TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for ALL in Remission
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of ALL in Remission
Treatment options for acute lymphoblastic leukemia (ALL) in remission include:
Consolidation therapy, including:
Source links and citations
Consolidation therapy, including:
Chemotherapy.
Consolidation therapy, including:
Ongoing treatment with a BCR::ABL1 tyrosine kinase inhibitor, such as imatinib, nilotinib, or dasatinib.
Consolidation therapy, including:
Autologous or allogeneic bone marrow transplant (BMT).
Central nervous system (CNS) prophylaxis therapy, including:
Source links and citations
Central nervous system (CNS) prophylaxis therapy, including:
Cranial radiation therapy plus intrathecal (IT) methotrexate.
Central nervous system (CNS) prophylaxis therapy, including:
High-dose systemic methotrexate and IT methotrexate without cranial radiation therapy.
Central nervous system (CNS) prophylaxis therapy, including:
IT chemotherapy alone.
Continue within this section
Preserved source evidence · Not medical advice